Background: Teratomas are a type of germ cell tumor, which are mostly benign, and dominative in adult females. Sacococcygeal teratomas are usually found in newborns or children, and can be detected prenatally;they are...Background: Teratomas are a type of germ cell tumor, which are mostly benign, and dominative in adult females. Sacococcygeal teratomas are usually found in newborns or children, and can be detected prenatally;they are exceedingly rare in adults. We reported a case of a sacrococcygeal teratoma in adult female. Case presentation: A 26-year-old female was diagnosed with a presacral tumor 6 years ago. Pelvic computed tomography (CT) demonstrated a presacral heterogeneous tumor, containing multi-located cystic area and enhanced solid component with calcification. Magnetic resonance imaging (MRI) showed a presacral non-enhanced cystic lesion with solid component, 128 mm × 104 mm × 102 mm, which was suspected of having invaded the rectal wall, fifth sacral vertebra (S5), and coccyx. She underwent abdomino-sacral total excision of tumor with coccygectomy. Histopathological examination revealed a tumor with intricate admixture of ectodermal (epidermis, sebaceous glands and squamous), mesenchymal (cartilage, adipose tissue, blood vessels, nerves and skeletal muscle) and endodermal components (respiratory epithelium and intestinal epithelium) respectively. After 24 months of follow-up the patient was both clinically and radiologically disease free. Conclusions: Early complete excision was the preferred definitive modality of treatment for sacrococcygeal teratoma, and multi-staged excision and reconstruction resulted in successful and safe treatment in our case.展开更多
Background: The SOFT study was a phase III trial designed to validate the non-inferiority of S-1 and oxaliplatin (SOX) plus bevacizumab to mFOLFOX6 plus bevacizumab in terms of PFS in patients with metastatic colorect...Background: The SOFT study was a phase III trial designed to validate the non-inferiority of S-1 and oxaliplatin (SOX) plus bevacizumab to mFOLFOX6 plus bevacizumab in terms of PFS in patients with metastatic colorectal cancer (mCRC) who had not previously received chemotherapy. In this study, we retrospectively reviewed cases in which S-1 plus bevacizumab as maintenance therapy after induction of S-1 and Oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy in patients with metastatic colorectal cancer was applied in order to evaluate its efficacy and safety in clinical practice. Material and method: Among the 40 patients with mCRC at the Fuchu Hospital who received SOX plus bevacizumab as a first line treatment between August 2013 and December 2018. The eligible patients had histologically confirmed mCRC. On day 1 of each 3-week period during the study, patients in the SOX plus bevacizumab received a 7.5 mg/kg intravenous infusion of bevacizumab, followed by an intravenous infusion of 130 mg/m2 oxaliplatin. S-1 (40 - 60 mg) was administered orally two times per day from after dinner on day 1 to after breakfast on day 15, followed by a 7-day rest. Results: The median PFS was 15.0 months and median OS was 36.0 months. The response rate (RR: complete pus partial response) was 85.0%, and the disease control rate (DCR: RR plus stable disease) was 92.5%. The most common adverse events with SOX plus bevacizumab were hypertension (50%), neurosensory toxicity (50%), anorexia (32.5%), fatigue (45%), pigmentation (39%), Neutrophil count decreased (30%), and platelet count decreased (40%). The most common grade 3/4 adverse events were neurosensory toxicity (5%) and fatigue (9%). Conclusion: This study revealed that the survival benefit of S-1 and oxaliplatin (SOX) plus bevacizumab in Japanese patients with mCRC was like that observed in previous clinical trials. Therefore, S-1 and oxaliplatin (SOX) plus bevacizumab can be considered as routine first-line treatment option for patients with mCRC.展开更多
文摘Background: Teratomas are a type of germ cell tumor, which are mostly benign, and dominative in adult females. Sacococcygeal teratomas are usually found in newborns or children, and can be detected prenatally;they are exceedingly rare in adults. We reported a case of a sacrococcygeal teratoma in adult female. Case presentation: A 26-year-old female was diagnosed with a presacral tumor 6 years ago. Pelvic computed tomography (CT) demonstrated a presacral heterogeneous tumor, containing multi-located cystic area and enhanced solid component with calcification. Magnetic resonance imaging (MRI) showed a presacral non-enhanced cystic lesion with solid component, 128 mm × 104 mm × 102 mm, which was suspected of having invaded the rectal wall, fifth sacral vertebra (S5), and coccyx. She underwent abdomino-sacral total excision of tumor with coccygectomy. Histopathological examination revealed a tumor with intricate admixture of ectodermal (epidermis, sebaceous glands and squamous), mesenchymal (cartilage, adipose tissue, blood vessels, nerves and skeletal muscle) and endodermal components (respiratory epithelium and intestinal epithelium) respectively. After 24 months of follow-up the patient was both clinically and radiologically disease free. Conclusions: Early complete excision was the preferred definitive modality of treatment for sacrococcygeal teratoma, and multi-staged excision and reconstruction resulted in successful and safe treatment in our case.
文摘Background: The SOFT study was a phase III trial designed to validate the non-inferiority of S-1 and oxaliplatin (SOX) plus bevacizumab to mFOLFOX6 plus bevacizumab in terms of PFS in patients with metastatic colorectal cancer (mCRC) who had not previously received chemotherapy. In this study, we retrospectively reviewed cases in which S-1 plus bevacizumab as maintenance therapy after induction of S-1 and Oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy in patients with metastatic colorectal cancer was applied in order to evaluate its efficacy and safety in clinical practice. Material and method: Among the 40 patients with mCRC at the Fuchu Hospital who received SOX plus bevacizumab as a first line treatment between August 2013 and December 2018. The eligible patients had histologically confirmed mCRC. On day 1 of each 3-week period during the study, patients in the SOX plus bevacizumab received a 7.5 mg/kg intravenous infusion of bevacizumab, followed by an intravenous infusion of 130 mg/m2 oxaliplatin. S-1 (40 - 60 mg) was administered orally two times per day from after dinner on day 1 to after breakfast on day 15, followed by a 7-day rest. Results: The median PFS was 15.0 months and median OS was 36.0 months. The response rate (RR: complete pus partial response) was 85.0%, and the disease control rate (DCR: RR plus stable disease) was 92.5%. The most common adverse events with SOX plus bevacizumab were hypertension (50%), neurosensory toxicity (50%), anorexia (32.5%), fatigue (45%), pigmentation (39%), Neutrophil count decreased (30%), and platelet count decreased (40%). The most common grade 3/4 adverse events were neurosensory toxicity (5%) and fatigue (9%). Conclusion: This study revealed that the survival benefit of S-1 and oxaliplatin (SOX) plus bevacizumab in Japanese patients with mCRC was like that observed in previous clinical trials. Therefore, S-1 and oxaliplatin (SOX) plus bevacizumab can be considered as routine first-line treatment option for patients with mCRC.
